Sight Sciences (SGHT) Stock Price, News & Analysis

Company Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $3.19 to $3.63
• 50-Day Range: $2.09 to $3.61
• 52-Week Range: $2.03 to $8.45
• Volume: 142,448 shs
• Average Volume: 214,445 shs
• Market Capitalization: $186.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.02
• Consensus Rating: Hold

Sight Sciences Stock Analysis - MarketRank™

Sight Sciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 365th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sight Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sight Sciences are expected to grow in the coming year, from ($0.99) to ($0.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sight Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sight Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sight Sciences has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.50% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Sight Sciences has recently decreased by 3.01%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sight Sciences does not currently pay a dividend.

Dividend Growth

Sight Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.50% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Sight Sciences has recently decreased by 3.01%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.24

News Sentiment

Sight Sciences has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Sight Sciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sight Sciences insiders have sold 196.71% more of their company's stock than they have bought. Specifically, they have bought $27,300.00 in company stock and sold $81,001.00 in company stock.

Percentage Held by Insiders

30.90% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGHT Stock Analysis - Frequently Asked Questions

How have SGHT shares performed this year?

Sight Sciences' stock was trading at $3.64 at the start of the year. Since then, SGHT stock has decreased by 0.8% and is now trading at $3.61.
View the best growth stocks for 2025 here.

How were Sight Sciences' earnings last quarter?

Sight Sciences, Inc. (NASDAQ:SGHT) issued its earnings results on Thursday, May, 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative net margin of 63.30% and a negative trailing twelve-month return on equity of 47.28%.
Read the conference call transcript.

When did Sight Sciences IPO?

Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share.

Who are Sight Sciences' major shareholders?

Sight Sciences' top institutional investors include Long Focus Capital Management LLC (6.05%), Acadian Asset Management LLC (0.84%), Charles Schwab Investment Management Inc. (0.43%) and Goldman Sachs Group Inc. (0.19%). Insiders that own company stock include Paul Badawi, D1 Capital Partners LP, David Badawi, Staffan Encrantz, Matthew Link, Sam Boong Park, Jeremy B Hayden and Manohar K Raheja.
View institutional ownership trends.

How do I buy shares of Sight Sciences?

Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sight Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SGHT
• CIK: 1531177
• Web: www.sightsciences.com
• Phone: 877-266-1144
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.02
• High Stock Price Target: $5.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.55 million
• Net Margins: -63.30%
• Pretax Margin: -63.04%
• Return on Equity: -47.28%
• Return on Assets: -32.72%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 10.18
• Quick Ratio: 9.74

Sales & Book Value

• Annual Sales: $78.11 million
• Price / Sales: 2.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 51,696,000
• Free Float: 36,087,000
• Market Cap: $186.62 million
• Optionable: Optionable
• Beta: 2.41